Extracted from this filing and checked against the source text.
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
PharmaCyte Biotech, Inc. shareholders approved Approval of Executive Compensation at the 2024-04-29 meeting.
- Proposal
- say on pay
- Outcome
- passed
- Meeting
- 2024-04-29
Exact text from the filing
Proposal 3. Approval of Executive Compensation. The approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers. For Against Abstain Non-Votes Broker Non-Votes 1,922,352 186,215 50,866 0 2,355,454
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
PharmaCyte Biotech, Inc. shareholders approved Election of Directors at the 2024-04-29 meeting.
- Proposal
- director election
- Outcome
- passed
- Meeting
- 2024-04-29
Exact text from the filing
Proposal 1. Election of Directors. The election of five directors, each to hold office until the annual meeting of stockholders for the year ended April 30, 2025 or until their respective successor is elected and qualified. Nominee For Withheld Broker Non-Votes Joshua N. Silverman 1,892,894 266,539 2,355,454 Jonathan L. Schechter 2,064,472 94,961 2,355,454 Michael M. Abecassis 1,579,782 579,651 2,355,454 Robert Weinstein 2,022,363 137,070 2,355,454 Wayne R. Walker 2,060,785 98,648 2,355,454
View on SEC.gov
Shareholder Votes
SEC 8-K Item 5.07
confidence 0.98
PharmaCyte Biotech, Inc. shareholders approved Ratification of Selection of Independent Registered Public Accounting Firm at the 2024-04-29 meeting.
- Proposal
- auditor ratification
- Outcome
- passed
- Meeting
- 2024-04-29
Exact text from the filing
Proposal 2. Ratification of Selection of Independent Registered Public Accounting Firm. The ratification of the selection by the audit committee of the board of directors of Marcum LLP as the independent registered public accounting firm of the Company for the fiscal year ending April 30, 2024. For Against Abstain 4,387,273 109,167 18,447
View on SEC.gov